1180112-41-7

Basic information

• Product Name: 7-Boc-1,7-diaza-spiro[3.5...
• Synonyms: 7-Boc-1,7-diaza-spiro[3.5...;tert-butyl 1,7-diazaspiro[3.5]nonane-7-carboxylate;7-Boc-1,7-diaza-spiro[3.5]nonane;7-Boc-1,7-diaza-spiro[3.5]nonane - D11421
• CAS NO: 1180112-41-7
• Molecular Formula: C₁₂H₂₂N₂O₂
• Molecular Weight: 226.31528
• Mol File: 1180112-41-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 319.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.08
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.74±0.20(Predicted)
• CAS DataBase Reference: 7-Boc-1,7-diaza-spiro[3.5...(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Boc-1,7-diaza-spiro[3.5...(1180112-41-7)
• EPA Substance Registry System: 7-Boc-1,7-diaza-spiro[3.5...(1180112-41-7)

Safety Data

• Hazardous Substances Data: 1180112-41-7(Hazardous Substances Data)

Usage

General Description

7-Boc-1,7-diaza-spiro[3.5]nonane is a chemical compound that belongs to a Family of organic chemicals known as spiro compounds. These are organic compounds containing a spirocycle, which is a ring system having two rings of different sizes that share one single atom (spiro atom) but no bonds. In 7-Boc-1,7-diaza-spiro[3.5]nonane specifically, the Boc part of its name indicates the presence of a tert-butyloxycarbonyl protecting group. This chemical group protects functional groups in an organic molecule from unwanted reactions. Source: PubChem National Library of Medicine. The compound can be used in various applications, in particular in the pharmaceutical industry, where it serves as a key intermediate for the synthesis of several therapeutic agents.

Upstream product

• 392331-78-1 tert-butyl 2-oxo-1,7-diazaspiro[3.5]nonane-7-carboxylate 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 159635-49-1 tert-butyl 4-methylidenepiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1333222-34-6 4-amino-4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 1312784-58-9 tert-butyl 4-amino-4-(2-hydroxyethyl)piperidine-1-carboxylate 

Relevant articles and documents

Synthesis method of 1,7-diazaspiro[3.5]nonane-7-tert-butyl formate

The invention provides a process synthesis method of 1,7-diazaspiro[3.5]nonane-7-tert-butyl formate. The synthesis method comprises the following five steps: 1, reacting a compound 1 with a bromine compound 2 and ammonium acetate by a one-pot method to obtain a compound 2; 2, reducing a compound 3 by using lithium borohydride to obtain a compound 4; 3, using triethylamine is used as alkali, and reacting the compound 4 with p-toluene sulfonyl chloride to generate a compound 5; 4, under the catalysis of potassium iodide, taking cesium carbonate as alkali, and carrying out ring closing on the compound 5 to generate a compound 6; and 5, under the action of magnesium chips, removing p-toluene sulfonyl from the compound 6 to obtain a compound 7. The method mainly solves the technical problem that no method suitable for industrial synthesis exists at present, and has the advantages that raw materials are easy to obtain, the total yield is high, and the method is suitable for industrial production.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.